Alexion’s newly approved rare-disease drug notches another clinical trial win
Alexion's newly approved rare-disease drug notches another clinical trial win — this time in patients with a rare type of kidney disease.
STAT+: Pharmalittle: We’re Reading About Amylyx Pulling Its ALS Drug, GLP-1 Drugs For Parkinson’s, And More
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
